Related Experiment Video
Updated: May 1, 2026
07:10
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
23.0K
Beta-blockers in liver cirrhosis.
Valerio Giannelli1, Barbara Lattanzi1, Ulrich Thalheimer2
1Gastroenterology Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy (Valerio Giannelli, Barbara Lattanzi, Manuela Merli).
Annals of Gastroenterology
|April 10, 2014
Summary
Non-selective beta-blockers (NSBB) are crucial for managing portal hypertension in cirrhosis, reducing bleeding risk. Current guidelines recommend NSBB for primary and secondary prophylaxis of variceal bleeding.
Area of Science:
- Hepatology
- Gastroenterology
- Pharmacology
Background:
- Non-selective beta-blockers (NSBB) are established in managing portal hypertension and reducing variceal bleeding risk in cirrhosis.
- Over 500 English articles detail NSBB use in cirrhosis, highlighting their evolving role.
Approach:
- Review of current literature and clinical guidelines on NSBB for variceal bleeding prophylaxis.
- Evaluation of NSBB efficacy in primary and secondary prophylaxis strategies.
- Consideration of additional benefits beyond bleeding risk reduction, such as reduced bacterial translocation.
Key Points:
- NSBB are not indicated for pre-primary prophylaxis of variceal bleeding.
- Primary prophylaxis involves NSBB or endoscopic band ligation for high-risk varices.
- Secondary prophylaxis recommends a combination of NSBB and endoscopic variceal ligation.
- Carvedilol may be more effective than propranolol in reducing portal pressure.
- Propranolol's potential adverse effects in refractory ascites require further investigation.
Conclusions:
- NSBB are a cornerstone therapy for cirrhotic patients with portal hypertension.
- The benefits of NSBB extend beyond bleeding risk reduction, potentially impacting overall patient outcomes.
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
382
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
01:22Heart Failure Drugs: β-Blockers
2.7K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.7K
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
4.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.2K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
01:28Antihypertensive Drugs: Types of β-Blockers
2.0K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K